Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer

被引：52

作者：

Chang, Yu-Ting ^{[1
]}

Chang, Ming-Chu ^{[1
]}

Wei, Shu-Chen ^{[1
]}

Tien, Yu-Wen ^{[2
]}

Hsu, Chiun ^{[3
]}

Liang, Po-Chin ^{[4
]}

Tsao, Po-Nien ^{[5
]}

Jan, I-Shiow ^{[6
]}

Wong, Jau-Min ^{[1
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan

[2] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan

[3] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan

[4] Natl Taiwan Univ Hosp, Dept Radiol, Taipei 100, Taiwan

[5] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 100, Taiwan

[6] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 100, Taiwan

来源：

PANCREAS | 2008年 / 37卷 / 02期

关键词：

vascular endothelial growth factor; placental growth factor; soluble vascular endothelial growth factor receptor 1; soluble fms-like tyrosine kinase 1; pancreatic adenocarcinoma; prognosis;

D O I：

10.1097/MPA.0b013e318164548a

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Objectives: Tumor angiogenesis is the consequence of an imbalance between positive and negative angiogenic regulatory factors. We sought to determine the role of pretreated serum angiogenic factors, including vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and soluble vascular endothelial growth factor receptor 1 (sVEGFR-1), in predicting clinical outcome in patients with pancreatic cancer. Methods: We assessed pretreated serum VEGF, PlGF, and sVEGFR-1 levels in 92 patients with pancreatic adenocarcinoma and 60 healthy control subjects using an enzyme-linked immunosorbent assay. The correlation between these angiogenesis-related factors and clinicopathologic factors, including staging and overall survival, was analyzed. Results: Serum levels of VEGF, PlGF, and sVEGFR-1 were significantly higher in patients with pancreatic cancer compared with those in controls (583.8 +/- 559.5 vs 187.63 +/- 393.32, 17.65 +/- 7.34 vs 10.93 +/- 1.21, and 50.94 +/- 51.17 vs 15.55 +/- 1.98 pg/mL, respectively; P < 0.0001). A reverse correlation was observed between sVEGFR-1 level and the advance of tumor stage. Cox regression analysis showed that the VEGF/sVEGFR-1 ratio was an independent predictor for pancreatic cancer survival. Higher VEGF/sVEGFR-1 ratio was significantly correlated with poor outcome in patents with pancreatic cancer. Conclusions: Vascular endothelial growth factor/sVEGF- 1 ratio is an independent prognostic factor for survival in pancreatic cancer. Its significance should be assessed when considering antiangiogenic therapy in treating pancreatic cancer patients.

引用

页码：145 / 150

页数：6

共 52 条

[1]

[Anonymous], [No title captured]

[2]

Arii S, 1999, Hum Cell, V12, P25

[3] Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer [J].

Bando, H ;

Weich, HA ;

Brokelmann, M ;

Horiguchi, S ;

Funata, N ;

Ogawa, T ;

Toi, M .

BRITISH JOURNAL OF CANCER, 2005, 92 (03) :553-561

[4] Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors [J].

Barleon B. ;

Reusch P. ;

Totzke F. ;

Herzog C. ;

Keck C. ;

Martiny-Baron G. ;

Marmé D. .

Angiogenesis, 2001, 4 (2) :143-154

[5]

Belgore FM, 2000, CIRCULATION, V102, pE108

[6] Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer [J].

John P Duffy ;

Guido Eibl ;

Howard A Reber ;

Oscar J Hines .

Molecular Cancer, 2 (1)

[7] Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells [J].

Dunk, C ;

Ahmed, A .

AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (01) :265-273

[8] Pancreatic cancer: a review of recent advances [J].

Eckel, Florian ;

Schneider, Guenter ;

Schmid, Roland M. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (11) :1395-1410

[9] Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma [J].

Ellis, LM ;

Takahashi, Y ;

Fenoglio, CJ ;

Cleary, KR ;

Bucana, CD ;

Evans, DB .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (03) :337-340

[10] Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers [J].

Eriksson, A ;

Cao, RH ;

Pawliuk, R ;

Berg, SM ;

Tsang, M ;

Zhou, D ;

Fleet, C ;

Tritsaris, K ;

Dissing, S ;

Leboulch, P ;

Cao, YH .

CANCER CELL, 2002, 1 (01) :99-108

← 1 2 3 4 5 6 →